drugset
drugset / Trial / NCT02931214

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers

NCT02931214 ↗

Phase 1 Completed 58 enrolled GlycoMimetics Incorporated Celerion · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate safety and pharmacokinetics of single ascending IV doses of GMI-1359 in healthy adult subjects.

Timeline

Start
2016-08
Primary completion
2017-10
Completion
2018-11

Drugs

EvaluationDrugModalityDoseRoute
Subject GMI-1359 Unknown — Intravenous

Indications

No indication recorded.